Neurologists Eye CAR T Therapies for Neuro-Immune Diseases, but Safety and Logistics Pose Adoption Hurdles
Event summary
- 77% of surveyed neurologists believe CAR T therapies could redefine neuro-immune disease management if proven safe and effective.
- Safety concerns, particularly cytokine release syndrome and neurotoxicity, are the top barrier to adoption, with 74% of neurologists citing this as a major hurdle.
- Descartes-08 from Cartesian Therapeutics is the most familiar CAR T therapy among neurologists, with nearly half reporting a highly favorable impression for gMG treatment.
- Operational challenges, including access to specialized treatment centers and logistical support, are expected to influence adoption alongside clinical outcomes.
The big picture
The potential of CAR T therapies to transform neuro-immune disease treatment is significant, but their adoption will hinge on overcoming safety concerns and logistical challenges. The therapies that succeed will need to demonstrate durable benefits while addressing practical realities of patient selection, treatment access, and physician support. Early adoption is likely to be concentrated in refractory patient populations, with broader use contingent on compelling clinical evidence and healthcare system readiness.
What we're watching
- Safety and Efficacy
- How emerging CAR T therapies will address long-term safety and durability concerns to gain broader acceptance.
- Operational Integration
- Whether the healthcare system can support the safe and practical use of CAR T therapies through specialized treatment centers and coordinated care models.
- Market Expansion
- The pace at which CAR T therapies move from highly specialized later-line treatments to broader use across neuro-immune diseases.
Related topics